BiogenUS09062X1037BIIBBIIB
Financials
Market Cap
$28.08B5Y beta
0.02EPS (TTM)
$7.979Free Float
144.36MP/E ratio (TTM)
24.21Revenue (TTM)
$9.84BEBITDA (TTM)
$2.54BFree Cashflow (TTM)
$1.24BPricing
Analyst Ratings
The price target is $297.80 and the stock is covered by 35 analysts.
Buy
24
Hold
11
Sell
0
Information
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.